# 3E Bioventures

> 3E Bioventures is a life sciences venture capital firm founded in 2015, investing in early and growth-stage biotech, TechBio and medical technology companies in the United States and China. Its portfolio spans new therapeutics, drug discovery platforms, diagnostics, scientific tools and medical imaging software.

- **Founded:** 2015
- **Headquarters:** Palo Alto, United States
- **Founders:** Qianye Karen Liu (Founding Partner)
- **Products:** Biotech venture investment, TechBio and medical technology investment, Portfolio company support, RMB and USD fund management
- **Notable:** Co-led Larkspur’s $35.5 million launch financing in 2023., Co-led Arnatar’s $52 million Series A, closed in 2024., Led Subtle Medical’s $12.2 million Series A in 2020; Subtle reported deployment on more than 1,300 scanners in June 2026.

## Products & services

- **Biotech venture investment** — Equity investment in early and growth-stage therapeutics companies, new modalities and drug discovery platforms.
- **TechBio and medical technology investment** — Backing for technologies at the intersection of biology and engineering, including scientific tools, diagnostics, biosensors and AI imaging software.
- **Portfolio company support** — Scientific and industry expertise, investor syndication and governance; Frank Yan joined Larkspur’s board at its 2023 launch.
- **RMB and USD fund management** — The firm states that it manages both RMB and US dollar funds investing in China and the United States.

## Achievements

- Co-led Larkspur’s $35.5 million launch financing in 2023.
- Co-led Arnatar’s $52 million Series A, closed in 2024.
- Led Subtle Medical’s $12.2 million Series A in 2020; Subtle reported deployment on more than 1,300 scanners in June 2026.
- Official portfolio includes publicly listed companies such as Twist Bioscience, Cytek Biosciences and C4 Therapeutics; listings do not establish realized fund returns.

## Latest updates

- **2026-10** — Portfolio company Subtle Medical announced distribution partners in the UK and Italy on October 20.
- **2026-09** — Lysoway published preclinical LW-1017 data; its September 14 announcement said the candidate was in Phase I healthy-volunteer evaluation. 3E’s news page carried the item on September 15.
- **2026-07** — Arnatar announced NMPA clearance to begin first-in-human testing of ART5 for ADPKD; clearance is not treatment approval.
- **2026-06** — Subtle Medical announced $33 million in growth capital and the appointment of Ohad Arazi as CEO; the announcement did not name 3E as a participant in that financing.
- **2025-10** — OncoC4 announced nearly $50 million in Series B financing with participation from existing investor 3E.

## Links

- Website: https://www.3ebiovc.com/
- LinkedIn: https://www.linkedin.com/company/3e-bioventures

---

Profile page: https://yespress.io/3e-bioventures
Published by YesPress — https://yespress.io
Last updated: 2026-10-27